{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang C"],"funding":["National Science and Technology Innovation 2030, Major Project- Research on Cancer, Cardiovascular, Respiratory and Metabolic Diseases","National Natural Science Foundation of China"],"pagination":["148"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11892250"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(1)"],"pubmed_abstract":["<h4>Background</h4>The association between lung microbiome and pulmonary hypertension (PH) remain unknown. This study aims to define the airway mycobiome signature and its potential correlation with clinical parameters of PH.<h4>Methods</h4>Overall, 244 patients with PH and 120 healthy controls (CON) were recruited from three independent centers. The PH group was divided into subgroups not using antibiotics or corticosteroids (non-ANT/CORT), and those using ANT, CORT, or ANT + CORT within 1 month, and clinical classification (Groups 1, 3, and 4), World Health Organization functional class (I-IV), and disease severity based on mean pulmonary artery pressure or pulmonary vascular resistance levels for in-depth comparison.<h4>Results</h4>Distinct airway mycobiome profiles were observed in PH,"],"journal":["BMC medicine"],"pubmed_title":["Distinct airway mycobiome signature in patients with pulmonary hypertension and subgroups."],"pmcid":["PMC11892250"],"funding_grant_id":["2024ZD0528700","82241012, 82270052, 82120108001, 82170065, 82170069, 82370063"],"pubmed_authors":["Zheng Y","Zhong B","Lu W","Liang W","Yang K","Xing Y","Jiang Q","Li P","Lin Z","Zhao Z","Wang J","Wu H","Hong C","Li Z","Zhang T","Zhang Z","Zhang Y","Chen Y","Liu C","Zhang C","Yuan JX","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"Distinct airway mycobiome signature in patients with pulmonary hypertension and subgroups.","description":"<h4>Background</h4>The association between lung microbiome and pulmonary hypertension (PH) remain unknown. This study aims to define the airway mycobiome signature and its potential correlation with clinical parameters of PH.<h4>Methods</h4>Overall, 244 patients with PH and 120 healthy controls (CON) were recruited from three independent centers. The PH group was divided into subgroups not using antibiotics or corticosteroids (non-ANT/CORT), and those using ANT, CORT, or ANT + CORT within 1 month, and clinical classification (Groups 1, 3, and 4), World Health Organization functional class (I-IV), and disease severity based on mean pulmonary artery pressure or pulmonary vascular resistance levels for in-depth comparison.<h4>Results</h4>Distinct airway mycobiome profiles were observed in PH,","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2025-04-22T20:48:01.178Z","creation":"2025-04-06T03:22:03.365Z"},"accession":"S-EPMC11892250","cross_references":{"pubmed":["40059138"],"doi":["10.1186/s12916-025-03982-7"]}}